Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc
Eva Poveda, Vincent SorianoDepartment of Infectious Diseases, Hospital Carlos III, Madrid, SpainAbstract: Maraviroc is the first CCR5 antagonist approved for the treatment of HIV-1 infection. It specifically inhibits the replication of R5 viruses by blocking viral entry. HIV-1 tropism can be estimat...
Saved in:
Main Authors: | Eva Poveda, Vincent Soriano |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2010
|
Subjects: | |
Online Access: | https://doaj.org/article/d00e38efa01d416dbaedef85485721bf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
by: Thore Lorenzen
Published: (2010) -
An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients
by: Putcharoen O, et al.
Published: (2013) -
Magnitude of cytopenias among HIV‑infected children in Bahir Dar, northwest Ethiopia: a comparison of HAART-naïve and HAART‑experienced children
by: Tsegay YG, et al.
Published: (2017) -
Poor immunological recovery among severely immunosuppressed antiretroviral therapy-naïve Ugandans
by: Nanzigu S, et al.
Published: (2013) -
Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir
by: D'Ambrosio R, et al.
Published: (2012)